Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy (CONCUR)

• ClinicalTrials.gov Identifier: NCT01584830
• Recruitment Status: Completed
• First Posted: April 25, 2012
• Last Update Posted: February 8, 2016
• Sponsor: Bayer
• Information provided by (Responsible Party): Bayer

Study Description

Brief Summary:

The purpose of this study is to assess if Regorafenib in combination with best supportive care will slow down tumor progression and result in increased survival in patients with metastatic colorectal cancer.

Condition or disease	Intervention/treatment	Phase
Colorectal Neoplasms	Drug: Regorafenib (BAY73-4506); Drug: Placebo	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 204 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
• Study Start Date: April 2012
• Actual Primary Completion Date: November 2013
• Actual Study Completion Date: January 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm 1	Drug: Regorafenib (BAY73-4506); Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
Placebo Comparator: Arm 2	Drug: Placebo; Placebo will be given 3 weeks on/1 week off (160 mg od po.)

Outcome Measures

Primary Outcome Measures :

1. Overall Survival (OS) [ Time Frame: From randomization of the first subject untill 154 death events observed, up to 2 years ]
   OS is defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.

Secondary Outcome Measures :

1. Progression-free Survival (PFS) [ Time Frame: From randomization of the first subject untill 154 death events observed, up to 2 years ]
   PFS was defined as the time from date of randomization to disease progression radiological/clinical or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation.
2. The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR). [ Time Frame: From randomization of the first subject untill 154 death events observed, up to 2 years ]
3. Disease Control Rate (DCR) [ Time Frame: From randomization of the first subject untill 154 death events observed, up to 2 years ]
   DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating)
4. Safety variables will be summarized using descriptive statistics based on adverse events collection [ Time Frame: From randomization of the first subject untill 154 death events observed, up to 2 years ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.
• Subjects with metastatic colorectal cancer(CRC) (Stage IV).
• Subjects must have failed at least two lines of prior treatment.

• Progression during or within 3 months following the last administration of approved standard therapies which must include a fluoropyrimidine, oxaliplatin and irinotecan.

  • Subjects treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy.
  • Subjects who progress more than 6 months after completion of oxaliplatin containing adjuvant treatment must be retreated with oxaliplatin-based therapy to be eligible.
  • Subjects who have withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease will also be allowed into the study.
  • Subjects may have received prior treatment with Avastin (bevacizumab) and/or Erbitux (cetuximab)/Vectibix (panitumumab) (if KRAS WT)
• Metastatic CRC subjects must have measurable or non measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 1.
• Life expectancy of at least 3 months.
• Adequate bone marrow, liver and renal function as assessed by the laboratory required by protocol.

Exclusion Criteria:

• Prior treatment with Regorafenib.
• Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
• Extended field radiotherapy within 4 weeks or limited field radiotherapy within 2 weeks prior to randomization.
• Cardiological disease including Congestive heart failure, Unstable angina, Myocardial infarction, Cardiac arrhythmias requiring anti-arrhythmic therapy.
• Uncontrolled hypertension. (Systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg despite optimal medical management).
• Subjects with phaeochromocytoma.
• Pleural effusion or ascites that causes respiratory compromise.
• Arterial or venous thrombotic or embolic events.
• Any history of or currently known brain metastases.
• Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.
• Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 week.

Contacts and Locations

Locations

China, Guangdong

Guangzhou, Guangdong, China, 510060

Guangzhou, Guangdong, China, 510080

China, Heilongjiang

Harbin, Heilongjiang, China, 150056

China, Jiangsu

Nanjing, Jiangsu, China, 210002

China, Shaanxi

Xi'an, Shaanxi, China, 710032

China, Shandong

Qingdao, Shandong, China, 266003

China, Sichuan

Chengdu, Sichuan, China, 610041

China, Zhejiang

Hangzhou, Zhejiang, China, 310016

China

Beijing, China, 100021

Beijing, China, 100071

Beijing, China, 100142

Changchun, China, 130021

Shanghai, China, 200030

Shanghai, China, 200032

Shanghai, China, 200080

Tianjin, China, 300060

Hong Kong

Shatin, New Territories, Hong Kong

Hong Kong, Hong Kong

Korea, Republic of

Seoul, Korea, Korea, Republic of, 138-736

Taiwan

Taipei, Taiwan, 10016

Taipei, Taiwan, 11217

Taoyuan, Taiwan, 333

Vietnam

Hanoi, Vietnam

Hcmc, Vietnam

Ho Chi Minh City, Vietnam, 84

Sponsors and Collaborators

Bayer

Investigators

• Study Director: Bayer Study Director; Bayer

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW; CONCUR Investigators. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13.

• Responsible Party: Bayer
• ClinicalTrials.gov Identifier: NCT01584830
• Other Study ID Numbers: 15808
• First Posted: April 25, 2012
• Last Update Posted: February 8, 2016
• Last Verified: February 2016

Keywords provided by Bayer:

Regorafenib; Colorectal; Metastatic

Additional relevant MeSH terms:

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases